Consequently, mice with a myeloid specific deletion of Camkk2 are protected from high fat diet-induced obesity, insulin resistance and hepatosteatosis, highlighting CAMKK2 as an attractive therapeutic target for the treatment of inflammatory and metabolic diseases. Here, CAMKK2 is linked to obesity due to melanocortin 4 receptor deficiency.